[Comment] SGLT2 inhibitor and incretin mimetic therapy for type 2 diabetes and chronic kidney disease

The pandemic of diabetes has become a global emergency. Despite increasing knowledge about diabetes prevention, this knowledge has not translated into action that effectively reduces diabetes prevalence in communities. The global picture projects an increase in people living with diabetes, from 425 million in 2017 to nearly 630 million by 2045,1 and such an increase also means more people with diabetes complications. Chronic kidney disease develops in almost half of people with type 2 diabetes and is the leading cause of end-stage kidney disease worldwide.

Bekijk het originele bericht